ArticleACS pharmacology & translational science2019

Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38.

Nicholas J H Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.